Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3592453rdf:typepubmed:Citationlld:pubmed
pubmed-article:3592453lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3592453lifeskim:mentionsumls-concept:C0085393lld:lifeskim
pubmed-article:3592453lifeskim:mentionsumls-concept:C0085315lld:lifeskim
pubmed-article:3592453lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:3592453pubmed:issue1lld:pubmed
pubmed-article:3592453pubmed:dateCreated1987-7-20lld:pubmed
pubmed-article:3592453pubmed:abstractTextCentral nervous system toxoplasmosis was diagnosed in 12 immunosuppressed patients, eleven of whom had AIDS. Fever (9/12), confusion (7/12) and focal neurological manifestations (6/12) were the main clinical signs. Lumbar puncture yielded abnormal cerebrospinal fluid in 6/6 cases. Cerebral computed tomographic scan abnormalities, homogenous (2/12) or ring-like (9/12) contrast-enhancing mass lesions and/or low density lesions (6/12), were present in all patients. Brain biopsy confirmed T. gondii infection in 7/8 cases. The combination pyrimethamine-sulfadiazine accounted for complete resolution (4/8) or partial improvement (4/8) in eight out of 12 patients. Mean duration of therapy was 6.5 months (1-21.5 months) in 11 patients. No relapse was observed. In three cases spiramycin was ineffective in the prevention of neurotoxoplasmosis.lld:pubmed
pubmed-article:3592453pubmed:languagefrelld:pubmed
pubmed-article:3592453pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3592453pubmed:citationSubsetIMlld:pubmed
pubmed-article:3592453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3592453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3592453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3592453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3592453pubmed:statusMEDLINElld:pubmed
pubmed-article:3592453pubmed:issn0003-410Xlld:pubmed
pubmed-article:3592453pubmed:authorpubmed-author:RegnierBBlld:pubmed
pubmed-article:3592453pubmed:authorpubmed-author:LeporeRRlld:pubmed
pubmed-article:3592453pubmed:authorpubmed-author:VildéJ LJLlld:pubmed
pubmed-article:3592453pubmed:authorpubmed-author:SaimotA GAGlld:pubmed
pubmed-article:3592453pubmed:authorpubmed-author:KatlamaCClld:pubmed
pubmed-article:3592453pubmed:authorpubmed-author:MathéronSSlld:pubmed
pubmed-article:3592453pubmed:issnTypePrintlld:pubmed
pubmed-article:3592453pubmed:volume138lld:pubmed
pubmed-article:3592453pubmed:ownerNLMlld:pubmed
pubmed-article:3592453pubmed:authorsCompleteYlld:pubmed
pubmed-article:3592453pubmed:pagination30-3lld:pubmed
pubmed-article:3592453pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:meshHeadingpubmed-meshheading:3592453-...lld:pubmed
pubmed-article:3592453pubmed:year1987lld:pubmed
pubmed-article:3592453pubmed:articleTitle[Cerebral toxoplasmosis in immunosuppressed patients: diagnosis and treatment].lld:pubmed
pubmed-article:3592453pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3592453pubmed:publicationTypeEnglish Abstractlld:pubmed